Read, pause, explore
Dulaglutide
Also listed as Trulicity
A reference to read with the sources beside you.
Status as of . The reference fields below define the scope of these labels.
Filed under Metabolism for browsing.
Reference fields
Sources for these fields- Approval scope
- Trulicity: specified type 2 diabetes populations.
- Route and formulation
- Subcutaneous injection.
- Mechanism
- GLP-1 receptor agonist fusion protein.
- Evidence
- Randomized studies.
- Limits of the evidence
- No weight-management indication.
- Safety context
- Not recommended for severe gastroparesis.
A closer reading
Make space for the question
An average result and a prediction for a particular case require different kinds of checking. A method could describe a group average closely while making poor predictions for individual records within that group. To assess a prediction, imagine setting aside observations before building the method, then comparing its forecasts with those untouched records. That exercise asks whether the method can handle cases it did not help summarize. Reading a group result alongside a prediction claim is therefore an invitation to look for a separate check, rather than assuming that a well described average supplies one.
Keep these questions nearby
- Is the report describing observed group results or forecasting individual records?
- What separate check shows how predictions perform on observations withheld during development?
- Could accurate group summaries coexist with large errors in individual predictions?
Sources
The references below accompany the entry as a whole. Dates show when each source was checked.
- TRULICITYNLM · Checked
Keep a little room for reading
Prepared by Healthy Pound Editorial Team. Educational reference; no clinical review is claimed. This page does not provide individual medical advice.